Progression-Free Survival– tag –
-
China Approves Satri-Cel, World’s First CAR T-Cell Therapy for Claudin 18.2-Positive Gastric Cancer
PubMed China Overview China's National Medical Products Administration (NMPA) has approved satricabtagene autoleucel (satri-cel), a CAR T-cell therapy for Claudin 18.2-positive, HER2-negative advanced gastric or gastroesophageal junction... -
CAR-T Cell Therapy for Multiple Myeloma: Real-World Data Validates Enduring Efficacy with 33% Five-Year Progression-Free Survival
Liv Hospital Turkey Overview Real-world data on CAR-T cell therapy for multiple myeloma reveals 33% of patients remained progression-free for five years after a single infusion. This robust evidence also showed an encouraging 66% progres... -
MD Anderson Reports 70% Response Rate with Novel Claudin-18.2-Targeted CAR-T Cell Therapy for Intractable Kidney Cancer
MD Anderson Newsroom USA Overview Researchers at MD Anderson Cancer Center announced a 70% objective response rate (ORR) in an early-phase clinical trial of a novel CAR-T cell therapy targeting Claudin-18.2 for patients with metastatic r... -
Real-World Data for Follicular Lymphoma CAR T-Cell Therapy Maintains Trial-Level Response Rates but Shows Shorter Progression-Free Survival
The Limbic Australia Overview A real-world analysis of commercial CAR T-cell therapies (axi-cel and tisa-cel) for relapsed/refractory follicular lymphoma (FL) demonstrated comparable response rates to those observed in clinical trials, d... -
Caribou Biosciences’ Off-the-Shelf Allogeneic CAR T Vispa-cel Shows Superior PFS to Approved Autologous CAR T Therapies in Lymphoma Phase 1
Fierce Biotech USA Overview Caribou Biosciences announced promising median progression-free survival (PFS) data from its Phase 1 clinical trial of vispacabtagene regedleucel (vispa-cel), an off-the-shelf allogeneic CAR T-cell therapy for... -
Genprex’s Reqorsa® Gene Therapy Extends Progression-Free Survival in NSCLC Patients with High Trop-2/Low PTEN Biomarkers, ASCO 2026 Data Shows
Genprex, Inc. USA Overview Genprex, Inc. presented positive clinical data on predictive biomarkers for its Reqorsa® gene therapy in non-small cell lung cancer (NSCLC) patients at the 2026 ASCO Annual Meeting. The data indicates that pati...
1